摘要
在"奥贝泰克"案中,加拿大联邦上诉法院认为被上诉人赛诺菲—安万特公司的行为并未指向涉诉专利,不满足专利权滥用的构成要件,驳回上诉人奥贝秦克公司的适用专利权滥用抗辩请求。加拿大以判例法发展出较为成熟合理的"专利权滥用抗辩原则",并与《竞争法》一起规制专利权滥用行为,确保权利人和社会公众的利益衡平。加拿大的务实立场和审慎态度对我国规制专利权滥用的立法、司法和企业"走出去"有启示并应予以借鉴。
In Apotex Inc. v. Sanofi-Aventis Canada Inc. & Schering Co. , the Canadian Fed- eral Court of Appeal denied the request of defence of patent misuse referred by one of the respondents, namely Sanofi-Aventis Canada Inc.. The Court held that the respondent's conduct was not related to the patent at issue and could not satisfy the requirements of defence to patent misuse. The defence to patent misuse has been developed well in Canadian case law for several decades, and it is working together with Canadian Competition Act to prevent patent abuse for the purpose of balancing the public interests and private parties concerned. The Canadian experience is worth learning for Chinese legislators, judges and has great implications for Chinese enterprises that are striking to expand to overseas markets.
出处
《中国社会科学院研究生院学报》
CSSCI
北大核心
2014年第3期69-73,共5页
Journal of Graduate School of Chinese Academy of Social Sciences
基金
教育部人文社会科学研究基金项目"‘世界专利制度'的发展及中国的应对"的阶段性成果
项目编号为:10YJ A820077
国家2011计划司法文明协同创新中心研究成果
关键词
专利权滥用
抗辩原则
加拿大专利法
加拿大竞争法
中国专利法第四次修改
patent misuse
defence to infringement
Canadian Patent Act
Canadian Competition Act
the 4th Amendment of Chinese Patent Law